Dr. Ernest Mario serves as a venture partner in Pappas Capital. He serves as an Advisory Board Executive at Metalmark Capital. He serves as Advisor at Delpor. He also served as Board Member at Delpor, Balance Therapeutics & Tonix Pharmaceuticals Holding. He also serves as Board Member at Silver Bullet Therapeutics. He also serves as Advisor at Tectonic Ventures. He began his career in 1966 as a pharmaceutical researcher at Strasenburgh Laboratories in Rochester, NY. He later held various management positions within SmithKline and Squibb Corp., overseeing operations, quality control, and manufacturing. He was elected to the Squibb Board in 1984. He joined Glaxo plc in 1986 and subsequently served as Chief Executive and Deputy Chairman. In 1993, he joined Alza Corporation as CEO, where he ultimately consummated with Johnson & Johnson one of the largest mergers in pharmaceutical history. In 2001, he founded Apothogen, a company involved in early-stage pharmaceutical development, which subsequently merged with IntraBiotics. He recently retired from Reliant Pharmaceuticals where he served as CEO and Chairman of the Board of Directors since 2003. He is an adjunct professor of pharmacy at the University of Rhode Island, and also holds honorary doctorates from the University of Rhode Island and Rutgers University. He also served as the Board Member at Boston Scientific. He also serves as Board Member at Fervent Pharmaceuticals. He serves as Board Member at Peninsula Skincare Labs. He is the Chairman of the board at Orbus Therapeutics. He previously served as a Chairman of Capnia and Chimerix. He received BS in Pharmacy from Rutgers University, an MS in Physical Sciences from the University of Rhode Island, and a Ph.D. in Physical Sciences from the University of Rhode Island.